Wormigin-I Tablet is a combination antiparasitic medication containing Ivermectin 6 mg and Albendazole 400 mg, indicated for the treatment of a broad spectrum of parasitic infections. Ivermectin acts by binding selectively to glutamate-gated chloride ion channels in invertebrate nerve and muscle cells, leading to paralysis and death of the parasite. Albendazole, a benzimidazole derivative, inhibits microtubule synthesis by binding to β-tubulin, impairing glucose uptake and depleting energy stores in susceptible helminths. This synergistic combination is effective against various intestinal and tissue nematodes, including strongyloidiasis, onchocerciasis, ascariasis, trichuriasis, hookworm infections, and neurocysticercosis. Wormigin-I is administered orally, with dosage and duration tailored to the specific parasitic infection and patient profile. It is generally well tolerated; however, adverse effects may include mild gastrointestinal disturbances, headache, dizziness, and transient elevation of liver enzymes. Caution is advised in patients with hepatic impairment, pregnant or lactating women, and those with hypersensitivity to either component. Prior to initiation, appropriate diagnostic evaluation and exclusion of Loa loa infection are recommended to prevent severe adverse reactions. Wormigin-I Tablet offers an effective therapeutic option for the management of mixed parasitic infestations, improving patient outcomes through its broad-spectrum antiparasitic activity.